XML 58 R50.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 26, 2023 | Mar. 30, 2023 | Jun. 30, 2023 | Jun. 30, 2023 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Net product revenue |  |  |  |  | $ 3,746,000 | $ 140,141,000 |
Deferred revenue, current portion |  |  |  |  | 1,642,000 | 1,189,000 |
Deferred revenue, long term |  |  |  |  | 1,294,000 | 2,727,000 |
Product Revenue, Net |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Net product revenue |  |  |  |  | 0 | 1,044,000 |
GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Development milestones recevied |  |  |  |  | 10,000,000 |  |
License agreement contract asset |  |  |  |  | 9,500,000 | 19,300,000 |
Exclusive License And Collaboration Agreement |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Non refundable upfront payment received |  |  |  |  |  |  | $ 10,000,000
Transaction price |  |  |  |  | 12,100,000 |  |
Fixed upfront cash payment |  |  |  |  | 10,000,000 |  |
Amount related to withholding tax obligations |  |  |  |  | 1,100,000 |  |
Asset Purchase Agreement | Cypralis Limited |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | 0 | 0 |
License Agreement | Waterstone Pharmaceutical HK Limited |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | 0 | 0 |
License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Success-based development milestones receivable |  |  |  | $ 45,000,000 |  |  |
Development milestones recevied |  |  | $ 25,000,000 |  |  |  |
Revenue recognized |  |  |  |  |  | 4,400,000 |
Non refundable upfront payment received |  | $ 90,000,000 |  |  |  |  |
Total transaction price |  |  |  | 136,100,000 |  |  |
Payment of transaction price |  |  |  | 90,000,000 |  |  |
License transfer performance obligation revenue |  |  |  | 130,100,000 |  |  |
Research and development activity |  |  |  | 4,800,000 |  |  |
Ongoing clinical and preclinical studies |  |  |  | $ 1,200,000 |  |  |
Unbilled receivable |  |  |  |  |  | 4,400,000 |
License Agreement | GlaxoSmithKline Intellectual Property | License Transfer |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | 1,100,000 | $ 1,700,000 |
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit |  | 77,500,000 |  |  |  |  |
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | $ 64,000,000 |  |  |  |  |  |
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 54,250,000 |  |  |  |  |  |
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 46,500,000 |  |  |  |  |  |
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit |  | 65,000,000 |  |  |  |  |
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 45,500,000 |  |  |  |  |  |
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 45,500,000 |  |  |  |  |  |
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 39,000,000 |  |  |  |  |  |
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit |  | 50,000,000 |  |  |  |  |
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 35,000,000 |  |  |  |  |  |
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 35,000,000 |  |  |  |  |  |
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payable upon achievement of threshold limit | 30,000,000 |  |  |  |  |  |
Completion FURI, CARES, and NATURE Clinical Studies | License Agreement |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Development milestones recevied | 10,000,000 |  |  |  |  |  |
Successful Completion of Mario Study | License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Development milestones recevied | 7,350,000 |  |  |  |  |  |
Maximum | Exclusive License And Collaboration Agreement |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Potential development and commercial milestones yet to receive |  |  |  |  | $ 110,000,000 |  |
Maximum | License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Regulatory milestone payments receivable | 49,000,000 | 70,000,000 |  |  |  |  |
Commercial milestones payments receivable | 57,500,000 | 115,000,000 |  |  |  |  |
Sales milestone payments receivable |  | 242,500,000 |  |  |  |  |
Development milestones receivable | 72,350,000 | $ 75,500,000 |  |  |  |  |
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payments receivable | 179,500,000 |  |  |  |  |  |
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payments receivable | 169,750,000 |  |  |  |  |  |
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Sales milestone payments receivable | 145,500,000 |  |  |  |  |  |
Maximum | Achivement of Two Interim Milestone of Ongoing Mario Study | License Agreement | GlaxoSmithKline Intellectual Property |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Development milestones receivable | $ 30,000,000 |  |  |  |  |  |
Sales Revenue Net | Customer Concentration Risk | Wholesaler One |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Percentage of gross revenue |  |  |  |  |  | 44.00% |
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Percentage of gross revenue |  |  |  |  |  | 28.00% |
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Percentage of gross revenue |  |  |  |  |  | 26.00% |

X
- Definition Amount related to withholding tax obligations. + References No definition available. + Details
Name: | scyx_AmountRelatedToWithholdingTaxObligations
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commercial milestones payments receivable. + References No definition available. + Details
Name: | scyx_CommercialMilestonesPaymentsReceivable
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and commercial milestones yet to receive. + References No definition available. + Details
Name: | scyx_DevelopmentAndCommercialMilestonesYetToReceive
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development milestones receivable. + References No definition available. + Details
Name: | scyx_DevelopmentMilestonesReceivable
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestones recevied. + References No definition available. + Details
Name: | scyx_DevelopmentMilestonesRecevied
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fixed upfront cash payment. + References No definition available. + Details
Name: | scyx_FixedUpfrontCashPayment
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement contract asset. + References No definition available. + Details
Name: | scyx_LicenseAgreementContractAsset
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License transfer performance obligation revenue. + References No definition available. + Details
Name: | scyx_LicenseTransferPerformanceObligationRevenue
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Ongoing clinical and preclinical studies expense. + References No definition available. + Details
Name: | scyx_OngoingClinicalAndPreclinicalStudiesExpense
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of transaction price + References No definition available. + Details
Name: | scyx_PaymentOfTransactionPrice
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regulatory milestone payments receivable. + References No definition available. + Details
Name: | scyx_RegulatoryMilestonePaymentsReceivable
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development activity expense. + References No definition available. + Details
Name: | scyx_ResearchAndDevelopmentActivityExpense
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales milestone payable upon achievement of threshold limit. + References No definition available. + Details
Name: | scyx_SalesMilestonePayableUponAchievementOfThresholdLimit
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sales milestone payments receivable + References No definition available. + Details
Name: | scyx_SalesMilestonePaymentsReceivable
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Success-based development milestones receivable. + References No definition available. + Details
Name: | scyx_SuccessBasedDevelopmentMilestonesReceivable
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total transaction price, + References No definition available. + Details
Name: | scyx_TotalTransactionPrice
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Transaction price. + References No definition available. + Details
Name: | scyx_TransactionPrice
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | scyx_UpfrontPaymentReceived
Namespace Prefix: | scyx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2 + Details
Name: | us-gaap_UnbilledContractsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=scyx_GlaxosmithklineIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=scyx_ExclusiveLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=scyx_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=scyx_CypralisLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=scyx_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=scyx_WaterstonePharmaceuticalHKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=scyx_LicenseTransferMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto200MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | scyx_RelaunchDateAxis=scyx_RelaunchDateOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | scyx_RelaunchDateAxis=scyx_RelaunchDateTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | scyx_RelaunchDateAxis=scyx_RelaunchDateThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto300MillionTo500MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto750MillionTo1BillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=scyx_CompletionFuriCaresAndNatureClinicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=scyx_SuccessfulCompletionOfMarioStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=scyx_AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=scyx_WholesalerOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=scyx_WholesalerTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=scyx_WholesalerThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |